BioPharmSignal logoBioPharmSignal

Biotech News

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio, Inc. (ETNB)89bio, Inc.Company update

SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that

Related news

NAMSNewAmsterdam Pharma2026-08-06 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-07-03 01:30 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALGSAligos Therapeutics2026-04-24 12:00 EST

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TERNTerns Pharmaceuticals2026-04-02 20:05 EST

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

MLYSMineralys Therapeutics2026-07-27 20:01 EST

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SGMTSagimet Biosciences2026-06-23 00:49 EST

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SGMTSagimet Biosciences2026-04-06 11:00 EST

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ALGSAligos Therapeutics2026-07-13 12:00 EST

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

View all latest news

89bio, Inc.

89bio is a liver and metabolic disease company focused on MASH and related liver biology. Its story is driven by the possibility of creating a major liver-disease franchise.

Recent company news

ETNB89bio, Inc.2025-09-18 05:02 EST

89bio, Inc. Announces Agreement to be Acquired by Roche

ETNB89bio, Inc.2025-09-05 20:05 EST

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB89bio, Inc.2025-08-28 20:05 EST

89bio to Participate in Upcoming Investor Conferences

ETNB89bio, Inc.2025-08-07 20:06 EST

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

ETNB89bio, Inc.2025-08-04 20:05 EST

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States